Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India.
J Microencapsul. 2011;28(8):717-28. doi: 10.3109/02652048.2011.615948. Epub 2011 Oct 10.
To achieve prolonged drug release for the treatment of multidrug resistant tuberculosis and to improve the patient compliance, ethionamide loaded PLGA nanoparticles were developed.
They were developed by solvent evaporation method and optimized. The optimized formulation was subjected to various physico-chemical characterization, in vitro release studies and in vivo tolerability study.
There was no significant drug-polymer interaction and drug was encapsulated as crystalline form in nanoparticles. In vitro release was sustained up to 15 days in various media. Ethionamide loaded nanoparticles in mice did not reveal any statistically significant treatment related effects on body weight gain and clinical signs. Likewise, no treatment-related toxic effect was found in hematology, clinical chemistry and histopathology. Our results indicate the development of an orally effective safe formulation of ethionamide with sustained release property.
Hence, ethionamide loaded nanoparticles offer excellent potential for further preclinical and clinical studies.
为了治疗耐多药结核病并提高患者的顺应性,实现药物的长效释放,开发了乙胺丁醇负载 PLGA 纳米粒。
采用溶剂蒸发法制备并优化。对优化后的配方进行了各种理化特性、体外释放研究和体内耐受性研究。
药物与聚合物之间没有明显的相互作用,药物以结晶形式包封在纳米粒中。在各种介质中,体外释放可持续 15 天。乙胺丁醇负载的纳米粒在小鼠体内未显示出任何与体重增加和临床症状相关的有统计学意义的治疗相关影响。同样,在血液学、临床化学和组织病理学方面也未发现任何与治疗相关的毒性作用。我们的结果表明,乙胺丁醇具有持续释放特性的口服有效安全制剂的开发具有巨大潜力。
因此,乙胺丁醇负载纳米粒为进一步的临床前和临床研究提供了极好的潜力。